Tracheal Squamous Cell Carcinoma Treated Endoscopically

Ly, Vanthanh; Gupta, Sandeep; Desoto, Fidelina; Cutaia, Michael

doi:10.1097/lbr.0b013e3181f1e809

Cited by 5 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the patients in the current study presented with locally advanced, stage 4 ACC (61%). Case reports suggest argon plasma coagulation (APC) and chemotherapy as alternative treatment options [22, 23]. However, APC is only suitable for the palliative tumor stage, and chemotherapy alone seems to be ineffective [24].…”

Section: Discussionmentioning

confidence: 99%

Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution

et al. 2019

View full text Add to dashboard Cite

Background Primary adenoid cystic carcinomas (ACCs) of the trachea are rare tumors of the central bronchial system. In patients presenting with unresectable tumors, severe comorbidities, or incomplete surgical resection, definitive radiotherapy is currently the recommended treatment. Irradiation with carbon ions (C 12 ) has shown promising local control (LC) and survival rates in cases of ACCs of the head and neck. No data on the therapeutic efficacy of C12 radiotherapy in treating tracheal ACC has been published. Methods All patients with histologically confirmed ACC of the trachea treated with surgery and/or radiation treatment at Heidelberg University Hospital between 1991 and 2017 were included in this analysis. Patient and treatment characteristics, short- and long-term toxicity after radiotherapy, overall survival (OS), freedom from local progression (FFLP), and freedom from distant progression (FFDP) were prospectively acquired and retrospectively analyzed. Results Thirty-eight patients (23 women and 15 men) with a median age of 51 were treated by surgery ( n = 20) and/or radiotherapy with either C 12 ( n = 7) or photons ( n = 24). Of these patients, 61% presented with locally advanced (stage 4) ACC. The median follow-up for all patients was 74.5 months. The 5-year OS for all patients was 95% (10-year: 81%). The 5-year FFLP and FFDP were 96% (10-year: 83%) and 69% (10-year: 53%), respectively. In patients who underwent surgery alone, the 5-year OS was 100% (10-year: 80%). The 5-year FFLP and FFDP were 100% (10-year: 100%) and 80% (10-year: 60%), respectively. In patients who underwent radiotherapy alone, the 5-year OS was 100% (10-year: 83%). The 5-year FFLP and FFDP were 88% (10-year: 44%) and 67% (10-year: 34%), respectively. In patients who received multi-modal treatment including surgery and adjuvant radiotherapy, the 5-year OS was 84% (10-year: 84%). The 5-year FFLP was 100% (10-year: 100%) and the 5-year FFDP was 65% (10-year, 65%). Conclusions The long-term prognosis is favorable if surgery is performed. In cases of an incomplete resection, good OS can still be achieved following adjuvant radiotherapy. For radiotherapy, irradiation with C 12 shows promising first results. However, more data is needed to prove the long-term advantage of C 12 over photons. Trial registration The ethics committee of the Heidelberg University Hospital approved the retrospective data analysis (S-174/2019).

show abstract

Section: Discussionmentioning

confidence: 99%

Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There remains a high mortality for patients with unresectable tracheal cancer and thus prompts an examination of the reported treatments for these patients, which has generally been limited to external beam RT, 4 , 11 , 12 , 13 , 16 with some reports of brachytherapy 9 , 12 and endotracheal ablation. 6 Review of the literature indicates that local recurrence is the most common pattern of failure for tracheobronchial SCC with rates between 19% and 73%. 5 , 8 , 13 However, distant failure is also substantial, reported between 13% and 46%, supporting the potential inclusion of chemotherapeutic regimens for the treatment of this disease.…”

Section: Discussionmentioning

confidence: 99%

“…of patients (SCC/total)Treatment (no. of patients)Radiation doseMedian survival5-y OS (%)Pattern of failureJoshi et al (2014) 2 9 totalChemo RT60-64 GyNRNRNRXie et al (2012) 3 66 SCC/156 totalRT (33)NR73 mo51.0NRNo RT (33)NA7 mo7.6NRAbbate et al (2010) 4 1 SCCRT50.4 Gy Boost to 61.2 Gy1 yNANRHetnał et al (2010) 5 24 SCC/50 totalSurgery + RT (3)∗64 Gy (definitive), 35 Gy (palliative)NR66∗5-y LRRFS 18%, 5-y DFS 15%RT (39)∗NR16∗Chemo-RT (4)∗NR0∗Ly et al (2010) 6 1 SCCEndotracheal ablation and XRT (1)66.6 Gy> 16 moNANRAhn et al (2009) 7 11 SCC/23 totalSurgery (6)NANR50NREBRT (2)NRNR0NRSurgery + EBRT (3)NRNR50NRGaissert et al (2004) 8 135 SCC/270 totalSurgical resection ± adjuvant EBRT (90)54 Gy adjuvant38 mo39NRDefinitive RT (45)60 Gy8.8 mo7.3NRThotathil et al (2004) 9 6 SCC/15 totalEBRT (3) or EBRT + ILRT (1)EBRT 10-56 GyILRT 15 Gy (LDR)38 mo∗37∗Local failure: 2/9Distant failure 4/9No treatment (2)NAVidetic et al (2003) 10 …”

Section: Introductionmentioning

confidence: 99%

Case report of tracheobronchial squamous cell carcinoma treated with radiation therapy and concurrent chemotherapy

Agrawal

Marcoux

Rabin

et al. 2016

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…Principal symptoms of pulmonary PSCC include cough, hemoptysis, and pulmonary infection, but asymptomatic patients also exist (4). Apart from radioactive examination such as computed tomography (CT) scanning, bronchoscopy biopsy allows for precise diagnosis of pulmonary PSCC (5). In addition, magnetic resonance imaging and positron emission tomography-CT (PET-CT) are also able to detect clinically invisible PSCC at an early…”

Section: Introductionmentioning

confidence: 99%

Pulmonary papillary squamous cell carcinoma: a population-based analysis of incidence, treatment, and prognosis

et al. 2019

View full text Add to dashboard Cite

Background: Pulmonary papillary squamous cell carcinoma (PSCC) is a rare variant of pulmonary squamous cell carcinoma (SCC). This study aims to improve relevant understanding and demonstrate the incidence, treatment, and prognosis of pulmonary PSCC using a population-based database. Methods: The Surveillance, Epidemiology and End Results (SEER) database was used to extract data of cases diagnosed with PSCC from 1973 to 2015 and analyze the incidence, treatment, and prognosis. Results: A total of 151 pulmonary PSCC cases were identified. The incidence of pulmonary PSCC cases in 2015 was 0.009 per 100,000 persons. The tumor grade of pulmonary PSCC cases was significantly lower than that of SCC cases (P<0.001). Both cancer-specific (CSS) and overall survival (OS) of pulmonary PSCC were significantly higher than those of other pulmonary SCCs (P<0.001). The outcomes of pulmonary PSCC cases receiving surgery were significantly better than cases without surgery (P<0.001). On the contrary, patients with radiotherapy had a worsened prognosis compared with those without radiotherapy (P<0.05). As expected, the prognosis of pulmonary PSCC cases receiving surgery was significantly better than that of pulmonary PSCC cases receiving chemotherapy and radiotherapy (both P<0.05). Conclusions: Our population-based evidence shows that pulmonary PSCC, as a rare cancer, has a better prognosis compared with other pulmonary SCCs. Surgery was the only effective treatment to improve CSS and OS, while chemotherapy was ineffective and radiotherapy worsened prognosis.

show abstract

Tracheal Squamous Cell Carcinoma Treated Endoscopically

Cited by 5 publications

References 7 publications

Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution

Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution

Case report of tracheobronchial squamous cell carcinoma treated with radiation therapy and concurrent chemotherapy

Pulmonary papillary squamous cell carcinoma: a population-based analysis of incidence, treatment, and prognosis

Contact Info

Product

Resources

About